Mental Health Clinics in Merrill, WI Accepting Medicare
5 Mental Health Clinics found. Showing 1 - 5
 Anderson & Associates Counseling And Psychologist Services Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 712 E 2nd St, Merrill, WI 54452 Phone: 715-539-8080 Fax: 715-539-8099 |
Visions Counseling Ii, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: N2355 Smith Rd, Merrill, WI 54452 Phone: 715-551-1970 Fax: 715-539-3580 |
Circle Of Joy Wellness Center Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: N2355 Smith Road, Merrill, WI 54452 Phone: 715-539-3580 |
Soul-full Solutions Counseling Center, Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 423 Grand Ave, Merrill, WI 54452 Phone: 715-805-6111 Fax: 715-539-8000 |
Melonas Counseling Services, Llc Counselor Medicare: Not Enrolled in Medicare Practice Location: 120 S Mill St, Merrill, WI 54452 Phone: 715-536-4440 Fax: 715-536-2736 |
News Archive
New pharmacogenetic test enables a personalized medicine approach
Luminex Corporation, today announced that it has commercially launched its first pharmacogenetic test, the xTAG CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Environmental factors more important than genetic for vertebral fracture
Individual-specific environmental factors such as lifestyle have a greater influence on vertebral fracture risk than genetic factors, suggest study findings.
More diverse SARS-CoV-2 variants identified within infected children than in adults
A new study describes the identification of multiple circulating variants of SARS-CoV-2 during this early pandemic period from Asia and Europe. In addition, there were multiple local introductions of different variants, that resulted in multiple waves of transmission.
Nymox nears completion of benign prostatic hyperplasia drug trial
Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.
› Verified 4 days ago